Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. develops plant-based compounds through its proprietary Botanical Synthesis technology platform, which is designed to grow plant compounds without cultivating the underlying plant. Company news centers on two business verticals: a direct-to-consumer products business built around proprietary nutraceutical health and wellness products, including VINIA, and a CDMO business serving customers seeking novel plant-based compounds.
Recurring updates include financial results, product commercialization, direct-to-consumer growth, CDMO development programs, and applications of the platform in areas such as nutraceuticals and fragrance molecules. BioHarvest also reports governance and leadership changes, equity-based compensation actions, financing activity, and conference participation tied to its public-company profile.
BioHarvest Sciences (NASDAQ:BHST) expanded its collaboration with Tate & Lyle to develop multiple plant-based sweetener molecules using BioHarvest's Botanical Synthesis™ platform.
The program targets sugar and calorie reduction, sugar-like taste, and responsible sourcing across diverse food and beverage categories, aligned with strong consumer demand for fruit- and plant-derived sweeteners.
BioHarvest Sciences (NASDAQ:BHST) reported Q1 2026 revenue of $8.5 million, up 8% year over year, with a 59% gross margin and net loss of $2.6 million. Full-year revenue guidance remains $42–$48 million.
CDMO revenue grew 135% YoY, supported by Stage 2 contracts worth over $2.2 million for rare fragrance and saffron programs. The VINIA brand reached 90,000 active users, with its Blood Flow Hydration product generating $920,000 in cumulative revenue and 20% of new customer revenue year-to-date.
BioHarvest Sciences (NASDAQ: BHST) appointed Nedira Salzman-Frenkel as Vice President of Business Development for its CDMO division. She will source and manage contracts across pharmaceutical, nutraceutical, nutrition, and cosmetic markets, supporting revenue targets and the planned launch of a new facility next year.
Salzman-Frenkel previously held senior roles in biotech, CRO, and pharma-focused businesses, including securing about $30 million in CRO contracts and leading a binding licensing term sheet with a top global pharmaceutical company for Phase 3 clinical development.
BioHarvest Sciences (NASDAQ: BHST) completed Stage 1 of a multi-stage CDMO development agreement with SaffronTech, establishing a stable saffron cell bank for nutraceutical and culinary uses. The agreement is valued at $1.125 million, with BioHarvest also holding a 25% stake in Saffron Composition and future royalty rights.
BioHarvest Sciences (NASDAQ: BHST) signed a $1.2 million Stage 2 CDMO contract to develop a rare fragrance raw material using its Botanical Synthesis platform. The deal follows Stage 1 completion in March 2026, when a stable cell bank containing rare molecules was created.
Stage 2, lasting about six to nine months, aims to produce enough material for commercial trials. BioHarvest keeps 20% ownership of successful compositions and is positioned to earn manufacturing revenue and future royalties, targeting production in the second half of 2027.
BioHarvest Sciences (NASDAQ: BHST) will report first quarter 2026 financial results before market open on Thursday, May 14, 2026.
The company will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss results and business operations; a replay will be posted in Investor Relations/Events & Presentations.
BioHarvest (NASDAQ: BHST) announced a strategic leadership transition effective April 29, 2026: Co-Founder Dr. Zaki Rakib assumes the role of Chief Executive Officer, consolidating R&D, Manufacturing, and Operations under the CDMO; Ilan Sobel moves from CEO to the Board to focus on D2C.
The change supports the company's stated "two-lens" strategy across the D2C VINIA business and its CDMO platform; fiscal year 2025 revenue was reported at approximately $35 million.
BioHarvest Sciences (NASDAQ: BHST) reported FY2025 revenue of $34.5M, up 37% year-over-year, and Q4 revenue of $9.1M, up 25% YoY. Gross margin was ~59% for FY2025. Cash and equivalents totaled $23.0M as of Dec 31, 2025. The company completed an oversubscribed institutional financing of $19.9M in November 2025 and raised an additional $10.9M from warrant exercises and debt conversions. 2026 consolidated revenue guidance is $42–48M with adjusted EBITDA loss guidance of ($3–4M). 2026 CDMO revenue guidance is $4–6M (total CDMO incl. intercompany $12–14M) with expected CDMO adjusted EBITDA loss of ($4–5M).
BioHarvest Sciences (NASDAQ: BHST) announced that its CDMO division completed Stage 1 of a multi-stage program, creating the first-ever stable cell culture for a rare, endangered fragrance plant using its Botanical Synthesis platform.
BioHarvest retains 20% ownership of developed compositions; biomass for pre-commercial testing is expected in 6–9 months, with industrial-scale manufacturing anticipated in 12–18 months. Company cites a $23B premium fragrance segment within a $58.9B industry opportunity.
BioHarvest Sciences (NASDAQ: BHST) announced that VINIA is the No.1 Resveratrol Polyphenol nutraceutical brand in the United States as of March 26, 2026.
Key metrics: U.S. revenue > $30 million in 2025, $85 million global cumulative revenue to date, ~85,000 active users, and VINIA.com accounts for ~80% of U.S. VINIA revenue. The company cites Botanical Synthesis technology that preserves plant-cell structure and magnifies piceid resveratrol up to 100x. The #1 ranking is based on NIQ 2025 market projections and Amazon sales estimates.